These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus. Kaneko M, Narukawa M. Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333 [Abstract] [Full Text] [Related]
10. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. Savarese G, Perrone-Filardi P, D'Amore C, Vitale C, Trimarco B, Pani L, Rosano GM. Int J Cardiol; 2015 Feb 15; 181():239-44. PubMed ID: 25528528 [Abstract] [Full Text] [Related]
11. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O'Keefe JH. Am J Cardiol; 2012 Sep 15; 110(6):826-33. PubMed ID: 22703861 [Abstract] [Full Text] [Related]
13. Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Xu S, Zhang X, Tang L, Zhang F, Tong N. Postgrad Med; 2017 Mar 15; 129(2):205-215. PubMed ID: 27813442 [Abstract] [Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, Wong E, Busse JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X. BMJ; 2016 Feb 17; 352():i610. PubMed ID: 26888822 [Abstract] [Full Text] [Related]
15. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study. Shih CJ, Chen HT, Kuo SC, Ou SM, Chen YT. J Am Med Dir Assoc; 2016 Jan 17; 17(1):59-64. PubMed ID: 26612484 [Abstract] [Full Text] [Related]
18. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. Savarese G, D'Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P. Int J Cardiol; 2016 Oct 01; 220():595-601. PubMed ID: 27390996 [Abstract] [Full Text] [Related]
19. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. Bonora E, Cigolini M. Nutr Metab Cardiovasc Dis; 2016 Apr 01; 26(4):273-84. PubMed ID: 27038847 [Abstract] [Full Text] [Related]
20. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. Saad M, Mahmoud AN, Elgendy IY, Abuzaid A, Barakat AF, Elgendy AY, Al-Ani M, Mentias A, Nairooz R, Bavry AA, Mukherjee D. Int J Cardiol; 2017 Feb 01; 228():352-358. PubMed ID: 27866027 [Abstract] [Full Text] [Related] Page: [Next] [New Search]